IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Guillermo MOR Application Serial No.: not yet assigned Application Filed: concurrently APOPTOSIS-BASED EVALUATION OF CHEMOSENSITIVITY IN CANCER For: **PATIENTS** U.S. Patent and Trademark Office Customer Service Window **Mail Stop New Application** Randolph Building 401 Dulany Street Alexandria, VA 22314 INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b) In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98. [X]Pursuant to 37 C.F.R. §1.98, a copy of each non-US patent document cited in the attached Form PTO/SB/08 is enclosed. No copies of the publications listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. _____ to which the above-identified

[] No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98.

application claims priority under 35 U.S.C. §120.

- [] Publication(s) ___ listed on the attached Form PTO/SB/08 were cited in a foreign search or examination report corresponding to ___ application serial no. ___ and mailed on ___.
- [] Enclosed is a copy of a non-English publication(s) ____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- [] Enclosed is a copy of a non-English publication(s) ____. English language publication ___ (copy enclosed) claims priority from this non-English publication.

[]		Elosed is an explanation of non-English publication(s) for which English translation is not available.				
[]	_	closed is an English translation of non-English publication(s) ed in the attached Form PTO/SB/08.				
[]	En	closed is a copy of pending patent Application Serial No				
Th time period		nation Disclosure Statement is filed within any one of the following				
	[]	within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);				
	[X	within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;				
	[]	before the mailing date of a first office action on the merits; or				
	[]	before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.				
It	is resp	ectfully requested that the Examiner consider the above-noted				
nformatio	n and	return an initialed copy of the attached Form PTO/SB/08 to the				
undersigne	ed.					
Dated: Ma	ay 22, 2	Respectfully submitted, COOLEY GODWARD LLP				
COOLEY G	• •					
ATTN: Pa Гhe Bowe		•				
_		V, Suite 800				
Washington, DC 20005-2221						
Fax: (202) 842-7899 Heather M. Boussios						
un. (202)	012 70	Reg. No. 52,704				

Please type a plus sign (+) inside this box ->

+

IAPZOREC'OPCT/PTO 22 MAY 2006

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/PTO		Complete if Known		
		Application Number	not yet assigned as a second a	
\mathbf{I}	NFORMATION DISCLOSURE	Filing Date	concurrently	
S	TATEMENT BY APPLICANT	First Named Inventor	Guillermo Mor	
		Group Art Unit	not yet assigned	
	(use as many sheets as necessary)	Examiner Name	not yet assigned	
Sheet	1 of 1	Attorney Docket Number	YALE-106/00US	

		OTHER – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1			
	1	Ofir et al., 2002, Taxol-Induced Apoptosis in Human SKOV3 Ovarian and MCF7 Breast Carcinoma Cells in Caspase-3 and Caspase-9 Independent, Cell Death and Differentiation, 9, 636-642.		
	2	Kolfschoten et al., 2002, Time-Dependent Changes in Factors Involved in the Apoptosis Process in Human Ovarian Cancer Cells as a Response to Cisplatin, Gynecologic Oncology, 84, 404-412.		
	3	Saito et al., 2004, Correlation Between Responsiveness of Neoadjuvant Chemotherapy and Apoptosis-Associated Proteins for Cervical Adenocarcinoma, Gynecologic Oncology, 92, 284-292.		

Examiner	Date	
Signature	Considered	•

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number (optional). ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.